Literature DB >> 21977602

[Prevalence of depression and anxiety in a cohort of 761 obese patients: impact in adherence to therapy and its outcome].

Rafael Violante1, Silvina Santoro, Claudio González.   

Abstract

OBJECTIVE: To determine the prevalence of psychiatric disorders in 761 obese patients, prospectively assessing their impact in both adherence to therapy and its outcome.
MATERIAL AND METHODS: Overweight and obesity were defined by body mass index (BMI), depression and anxiety according to "The Hospital Anxiety and Depressio Scale". Patients received a physical and biochemical evaluation, a hypochaloric diet and a training plan. Sibutramine was prescribed as anti-obesity drug.
RESULTS: The mean age was 31,28 (SD 11,26) years. 74.77% were women. The mean weight was 91.36 kg with a BMI of 34,49 Kg/m2 (SD 6,29). The prevalence of possible, probable and definite anxiety/depression was: 56.3%/22.0%, 29.8%/6.2%, and 7.2%/0.8% respectively. Both initial and final weight and BMI were higher in definite and probable depression respectively, with a minor percentage of weight loss likewise.
CONCLUSIONS: The studied psychiatric disturbances were prevalent in our population. Initial and final weight and BMI were higher in groups with more severe anxiety or depression. The percentage of weight loss and adherence to therapy were greater in groups of milder psychiatric disorders.

Entities:  

Mesh:

Year:  2011        PMID: 21977602

Source DB:  PubMed          Journal:  Vertex        ISSN: 0327-6139


  3 in total

1.  The DSM-5 effect: psychological characteristics of new patients affected by Binge Eating Disorder following the criteria of the DSM-5 in a sample of severe obese patients.

Authors:  Piergiuseppe Vinai; Annalisa Da Ros; Silvia Cardetti; Halpern Casey; Stacia Studt; Nicola Gentile; Anna Tagliabue; Luisa Vinai; Paolo Vinai; Cecilia Bruno; Giovanni Mansueto; Sara Palmieri; Maurizio Speciale
Journal:  Eat Weight Disord       Date:  2015-09-15       Impact factor: 4.652

2.  An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.

Authors:  Elvira Anna Carbone; Mariarita Caroleo; Marianna Rania; Giuseppina Calabrò; Filippo Antonio Staltari; Renato de Filippis; Matteo Aloi; Francesca Condoleo; Franco Arturi; Cristina Segura-Garcia
Journal:  Eat Weight Disord       Date:  2020-04-30       Impact factor: 4.652

3.  ZumBeat: Evaluation of a Zumba Dance Intervention in Postmenopausal Overweight Women.

Authors:  Anja Rossmeissl; Soraya Lenk; Henner Hanssen; Lars Donath; Arno Schmidt-Trucksäss; Juliane Schäfer
Journal:  Sports (Basel)       Date:  2016-01-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.